Showing results (41-50 of 528) with videos related to

Sort By:
Pageof 53
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2016
Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?Sophie Whyte, Simon Dixon, Rita Faria, et al.
Pharmacoeconomics|September 5, 2008
Exploring uncertainty in cost-effectiveness analysisKarl Claxton
Health Economics|May 31, 2007
OFT, VBP: QED?Karl Claxton
Open Heart|January 4, 2018
Impact of missed treatment opportunities on outcomes in hospitalised patients with heart failureSimon Walker, Eldon Spackman, Nathalie Conrad, et al.
Pharmacoeconomics|September 5, 2008
Subgroups and heterogeneity in cost-effectiveness analysisMark Sculpher
Nature Medicine|September 11, 2012
Straight talk with... Mark Sculpher. Interview by Kate RaviliousMark Sculpher
International Journal of Technology Assessment in Health Care|April 16, 2010
Cost-effectiveness of enhanced external counterpulsation (EECP) for the treatment of stable angina in the United KingdomClaire McKenna, Neil Hawkins, Karl Claxton, et al.
Pharmacoeconomics|June 18, 2005
Incorporation of uncertainty in health economic modelling studiesAnthony O'Hagan, Christopher McCabe, Ron Akehurst, et al.
Health Technology Assessment (Winchester, England)|March 18, 2016
The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infectionNicholas I Paton, Wolfgang Stöhr, Lars Oddershede, et al.
Pharmacoeconomics|March 12, 2016
Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT TrialLars Oddershede, Simon Walker, Wolfgang Stöhr, et al.
Pageof 53